Iressa (gefitinib) is a small molecule pharmaceutical. Gefitinib was first approved as Iressa on 2003-05-05. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against epidermal growth factor receptor.
|Indication||non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors|